Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$1.8 - $3.19 $676,128 - $1.2 Million
375,627 Added 179.6%
584,779 $1.1 Million
Q1 2023

May 15, 2023

BUY
$2.01 - $4.17 $104 - $216
52 Added 0.02%
209,152 $577,000
Q4 2022

Feb 14, 2023

SELL
$1.78 - $3.64 $26 - $54
-15 Reduced 0.01%
209,100 $414,000
Q3 2022

Nov 14, 2022

BUY
$2.89 - $5.32 $2 - $5
1 Added 0.0%
209,115 $621,000
Q2 2022

Aug 15, 2022

SELL
$3.27 - $8.76 $13,563 - $36,336
-4,148 Reduced 1.95%
209,114 $721,000
Q1 2022

May 16, 2022

SELL
$7.56 - $14.3 $8,694 - $16,445
-1,150 Reduced 0.54%
213,262 $1.75 Million
Q4 2021

Feb 14, 2022

BUY
$12.24 - $21.25 $770,422 - $1.34 Million
62,943 Added 41.56%
214,412 $3.06 Million
Q3 2021

Nov 15, 2021

SELL
$16.69 - $26.05 $2.16 Million - $3.37 Million
-129,400 Reduced 46.07%
151,469 $2.91 Million
Q2 2021

Aug 16, 2021

BUY
$18.15 - $27.75 $2.6 Million - $3.98 Million
143,450 Added 104.39%
280,869 $7.11 Million
Q1 2021

May 17, 2021

SELL
$20.71 - $51.02 $41,854 - $103,111
-2,021 Reduced 1.45%
137,419 $3.38 Million
Q4 2020

Feb 16, 2021

BUY
$21.84 - $44.0 $2.13 Million - $4.3 Million
97,712 Added 234.16%
139,440 $5.11 Million
Q3 2020

Nov 13, 2020

BUY
$13.63 - $24.12 $568,752 - $1.01 Million
41,728 New
41,728 $904,000
Q1 2020

May 15, 2020

SELL
$4.75 - $12.41 $174,477 - $455,844
-36,732 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$8.73 - $12.95 $691,634 - $1.03 Million
-79,225 Reduced 68.32%
36,732 $400,000
Q3 2019

Nov 14, 2019

BUY
$14.16 - $25.34 $200,718 - $359,194
14,175 Added 13.93%
115,957 $1.7 Million
Q2 2019

Aug 14, 2019

BUY
$27.0 - $30.25 $2.75 Million - $3.08 Million
101,782 New
101,782 $2.76 Million

Others Institutions Holding PSNL

About Personalis, Inc.


  • Ticker PSNL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 45,918,400
  • Market Cap $159M
  • Description
  • Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or pla...
More about PSNL
Track This Portfolio

Track Fred Alger Management, LLC Portfolio

Follow Fred Alger Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fred Alger Management, LLC with notifications on news.